The PANTS extension study and anti-TNF prescribing

ATOMIC IBD UNCUT - Episode 3
The new PANTS extension study published today in Lancet Gastroenterology and Hepatology (open access to the full paper here www.sciencedirect.com/science...)
After 3 years of therapy only 1/3 infliximab and 1/3 adalimumab patients are still on drug in remission
• notable that proportion exiting due to drug failure higher with ADA versus IFX (remember this is NOT randomised head-to-head)
Most important new insight with infliximab:
•⁠ ⁠start AZA before or at the same time as IFX
•⁠ ⁠use a full dose of AZA (at least early on)
Dose intensification in the context of immunogenicity does not work for very long
Plenty to think about here alongside PROFILE
Newly diagnosed moderate and moderate to severe Crohn’s = IFX plus full dose AZA

[@44DentalCare]

Your videos are very informative and clear to understand. My daughters ulcerative colitis is well controlled after the advise you had given via an online consultation. Keep up with your good work. Your videos are very helpful.

[@thomaslfuller]

Thanks Charlie - really helpful

[@tallula1percy]

I started with azathioprine but had an allergic reaction with infliximab it caused drug induced Demyelinating Lesions

[@michellereidy5750]

Sadly Infliximab didnt work well for my son when finally diagnosed in 2020, crohns was too severe and damage already done, hes recently started risankizumab(Skyrizi) so far so good! Hoping this will be the one to keep him well.